With Kenai Therapeutics emerging from stealth with an $82 Million Series A funding round, 2024 has started strong for iPSC drug developers looking to showcase the potential of their pipelines ahead of the next wave of investment. Introducing the 4^th iPSC Drug Development & Manufacturing Summit, your longest standing and definitive iPSC focused platform.

No iPSC stone will be left unturned, as key industry experts including Kenai Therapeutics, Cytovia Therapeutics, Aspen Neuroscience, NIST and many more, unite under one roof to transform the future of iPSC cell therapies. For the first time in 4 years, uniting R&D teams, manufacturing experts and business leaders, across 2 tracks of content for 3-days of cutting edge data presentations and strategic cross-functional discussions. Take a look at the full session details today.

With all this and more, don’t miss this golden opportunity to help you and your entire team stay at the forefront of the iPSC cell therapy revolution!